drug development

cost cutting restructuring savings reduce spend

Pharma

InflaRx charts layoffs, cost cuts to lift lead asset's prospects

Roughly 30% of the company’s staff will be laid off, accompanied by “substantial spending reductions,” InflaRx said in its announcement.

Fraiser Kansteiner Jan 8, 2026 11:03am

game over pivot new direction

InflaRx may find path forward for COVID drug in skin disorder

Jan 2, 2026 10:25am

Argenx

Argenx cans Vyvgart trials in thyroid eye disease over futility

Dec 15, 2025 10:00am

two jiggsaw puzzles connected with drawn hands shaking on the two puzzles

CDMOs Bora, Corealis unite for end-to-end oral solid dose work

Dec 9, 2025 4:44pm

Teva’s CEO shares ‘Pivot to Growth’ progress

Jun 27, 2025 9:00am

Clock in front of the subway

Fierce Biotech

FDA 'on track' to meet all PDUFA dates, Marty Makary says

Jun 18, 2025 4:00am